ClinicalTrials.gg
Not yet recruitingNCT07854457Updated Oct 2, 2026

Dual-Action Lenses for Slowing Myopia in Children and Teens: A Randomized, Double-Blind Trial

An interventional study of Dual-Action Myopia-Control Spectacle Lens and Stellest Myopia-Control Spectacle Lens(Highly Aspherical Lenslet Target / HALT Lens) in Myopia and Refractive Errors, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
6 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center — 21 open to participants now, 22 under way, none of them phase 3. Myopia · Shanghai Eye Disease Prevention and Treatment Center.

Planned enrollment
23rd of 36
120 · median 141
Started
2026
with 9 others
No phase
32 of 42
18 open now
Primary completion
2028-02
later than 17 of 21 live
Registered
41st of 42
by date

Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, this one is the 23rd largest by planned enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2026, is one of 32 with no phase, reaches primary completion later than 17 of the 21 other live ones, and was the 41st registered.

Myopia

1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

21 of the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 14 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, controlled study to test whether a new type of eyeglass lens - a "dual-action" lens that combines two technologies (multiple defocus zones and dot diffusion) - can slow the progression of nearsightedness (myopia) in children and teenagers.

About the participants: Children and adolescents with myopia who meet the study requirements will be randomly assigned (like flipping a coin) to one of two groups. One group will wear the new dual-action lenses, and the other group will wear Stellest lenses, an established myopia-control lens. Neither the participants, their families, nor the eye doctors doing the follow-up exams will know which lens each child is wearing.

About the study: Participants wear their assigned glasses at least 12 hours every day for 12 months and visit the clinic about every 3 months (5 visits in total). At each visit, doctors check eyesight, measure the length of the eyeball, and perform other eye exams. The main goal is to compare how much myopia progresses in the two groups after 12 months, measured by a painless dilated-eye (cycloplegic) refraction test. The study also tracks how comfortable and acceptable the lenses are, and how long children actually wear them each day.

Why this research matters: Myopia in children is increasing worldwide, and effective ways to slow it down are still limited. This study will show whether combining two proven optical technologies in one lens works as well as existing options and is safe and comfortable for daily wear.

03

Conditions studied

  • Myopia
  • Refractive Errors

Keywords

  • myopia
  • Refractive Errors
04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 6-14 years.
  2. After cycloplegia with 1% cyclopentolate hydrochloride eye drops (Cyclogyl/Saifeijie), spherical equivalent (SE) of both eyes between -0.50 D and -4.00 D.
  3. Astigmatism of both eyes ≤ 1.50 D; anisometropia ≤ 1.50 D. Best-corrected visual acuity (BCVA) ≥ 5.0.
  4. No use of myopia-control methods within the past 3 months, including defocus lenses, dot diffusion lenses, orthokeratology lenses, defocus soft contact lenses, progressive-addition spectacles, atropine eye drops, red-light therapy, or acupuncture.
  5. Able and willing to wear the study lenses at least 12 hours per day.
  6. Able to attend all scheduled follow-up visits over 12 months (4 follow-up visits after baseline).
  7. Willing to participate, with written signed by the legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Current or past glaucoma, corneal disease, or other organic eye diseases.
  2. Significant systemic disease, psychiatric disorder, or systemic collagen metabolic disease. Diagnosed amblyopia, constant strabismus, or other congenital eye diseases.
  3. Allergy to the materials or products of the study lenses.
  4. Allergy to cycloplegic agents or other ophthalmic examination medications.
  5. Unable to understand the study content or unable to cooperate with follow-up.
  6. Any other condition considered by the investigator to make the participant unsuitable for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Dual-Action Lenses

    Device: Dual-Action Myopia-Control Spectacle Lens

  • Active comparator
    Stellest Lenses

    Participants in this arm wear Stellest myopia-control spectacle lenses, an established myopia-control lens with highly aspherical lenslet target (HALT) technology that is already marketed. Participants are instructed to wear the assigned lenses at least 12 hours per day for 12 months. The follow-up schedule and examinations are identical to those in the experimental arm. Neither the participants, their guardians, nor the follow-up examiners know which lens is being worn.

    Device: Stellest Myopia-Control Spectacle Lens(Highly Aspherical Lenslet Target / HALT Lens)

Interventions

  • DeviceDual-Action Myopia-Control Spectacle Lens

    Spectacle lenses that combine two myopia-control optical technologies in a single lens: multiple defocus zones (multipoint peripheral defocus design) and dot diffusion technology (a light-scattering treatment that reduces contrast of the peripheral retinal image). The two technologies are intended to act together to slow axial elongation and myopia progression. Lenses are worn as daily-wear spectacles, with participants instructed to wear them at least 12 hours per day throughout the 12-month study period. This lens is investigational and not currently marketed.

  • DeviceStellest Myopia-Control Spectacle Lens(Highly Aspherical Lenslet Target / HALT Lens)

    Stellest spectacle lenses incorporate Highly Aspherical Lenslet Target (HALT) technology: a constellation of highly aspherical micro-lenslets distributed across the lens surface, which creates a volume of myopic defocus in front of the retina to slow eye growth. Lenses are worn as daily-wear spectacles, with participants instructed to wear them at least 12 hours per day throughout the 12-month study period. Stellest is an established, marketed myopia-control lens used here as the active comparator.

06

What researchers measure

Primary outcomes

  1. Change in Cycloplegic Spherical Equivalent (SE) From Baseline at 12 Months

    The primary efficacy outcome is the change in spherical equivalent (SE, in diopters) measured by cycloplegic (dilated-eye) refraction from baseline to Month 12. SE is calculated as sphere + ½ × cylinder. Cycloplegic refraction is performed after administration of cycloplegic eye drops, using the same autorefractor and standardized procedure at each visit. A smaller change (less myopic shift) indicates better myopia control. The right eye is designated as the study (observation) eye.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Change in Axial Length (AL) From Baseline at 12 Months

    Change in axial length (mm) measured by ocular biometry (e.g., IOLMaster) from baseline to Month 12 in the study eye. A smaller increase indicates better myopia control. AL is also assessed at Months 3, 6, and 9.

    Time frame: Baseline and Month 12

Other outcomes

  1. Corneal Curvature

    Corneal curvature (K values) measured by corneal topography/keratometry at each visit, as part of routine ocular assessment.

    Time frame: Baseline and Months 3, 6, 9, 12

  2. Exploratory Analysis of Factors Associated With Myopia Progression and Myopia-Control Practice

    Exploratory analysis of factors such as age at myopia onset, sex, daily wearing time, and visual habits (e.g., near-work and outdoor time), based on questionnaire data, to understand myopia-control diagnosis and treatment patterns in children and adolescents.

    Time frame: Collected at baseline and throughout the 12-month study period

07

Study locations

1 site
08

References and documents

Publications

  • Bao J, Yang A, Huang Y, Li X, Pan Y, Ding C, Lim EW, Zheng J, Spiegel DP, Drobe B, Lu F, Chen H. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-1176. doi: 10.1136/bjophthalmol-2020-318367. Epub 2021 Apr 2. PubMed 33811039 ↗
  • Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen H. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 2022 May 1;140(5):472-478. doi: 10.1001/jamaophthalmol.2022.0401. PubMed 35357402 ↗
  • Rappon J, Chung C, Young G, Hunt C, Neitz J, Neitz M, Chalberg T. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023 Nov;107(11):1709-1715. doi: 10.1136/bjo-2021-321005. Epub 2022 Sep 1. PubMed 36126105 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2028, 16 months later.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 16 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartEst.
Oct 5, 2026
Primary completionEst.
Feb 28, 2028
CompletionEst.
Apr 30, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854457
Lead sponsor
Shanghai Eye Disease Prevention and Treatment Center
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 5, 2026 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

WEI XU Principal Investigator
Contact
vvxuwei@163.com
+8618521513008

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion